Milan – October 09, 2026 -- WuXi Biologics is pitching a European manufacturing footprint of 54,000 L of drug-substance capacity in Dundalk, Ireland, plus a 12,000 L site in Wuppertal, Germany, to biopharma clients at CPHI Milan 2026, as Europe's biologics market is projected to grow from an estimated US$123.75 billion in 2025 to about US$269.65 billion by 2035.

The market is forecast to expand at a CAGR of 8.1% from 2026 to 2035. CPHI Milan 2026 brings together more than 62,000 pharmaceutical professionals and 2,900 exhibitors.